EDUCATIONAL SESSIONS
8:30 a.m. to 10:00 a.m.
EMT, Polarity, Cancer Etiology, and Prevention
Co-Chairpersons: Neil W. Gibson, OSI Pharmaceuticals, Inc., Melville, NY and Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA
Overview
Neil W. Gibson
Cell Signaling in Cell Polarity and EMT-Convergence of Wnt, Beta-catenin, and Cadherin Pathways
W. James Nelson, Stanford University, Stanford, CA
Migrating Cancer Stem Cells: An Integrated Concept of Malignant Tumor Progression
Thomas Brabletz, University of Erlangen, Erlangen, Germany
Therapeutic Opportunities Associated with EMT and Cancer Prevention
Neil W. Gibson
Role of Primary Care Physicians in Cancer Prevention Research and Practice
Chairperson: Sherri Sheinfeld-Gorin, Columbia University, New York, NY
Overview
Sherri Sheinfeld-Gorin, Columbia University, New York, NY
Using Decision Aids to Improve Colorectal Cancer Screening in Primary Care
Michael Pignone, University of North Carolina, Chapel Hill, NC
Towards Achieving the Full Potential of Primary Care in Cancer Prevention
Allen J. Dietrich, Dartmouth Medical School, Hanover, NH
Measuring and Improving Primary Care Performance in Cancer Screening
Bruce E. Landon, Harvard Medical School, Boston, MA
Update on SNPs and Haplotypes
Chairperson: Regina M. Santella, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY
Overview
Regina M. Santella
Evaluating Genetic Susceptibility with Genomewide Association Studies
John S. Witte, University of California, San Francisco, CA
Genetic Susceptibility
Ellen L. Goode, Mayo Clinic College of Medicine, Rochester, MN
Genetic Variation and Cancer
Matthew L. Freedman, Dana-Farber Cancer Institute, Boston, MA
EDUCATIONAL SESSIONS
10:15 a.m. to 11:45 a.m.
Biostatistics: Applications in Cancer Prevention Research
Chairperson: Susan G. Hilsenbeck, Baylor College of Medicine, Houston, TX
Overview
Susan G. Hilsenbeck
Designs for Early Phase Randomized Biomarker Chemoprevention Trials
Kyungmann Kim, University of Wisconsin, Madison, WI
Simple Designs for Phase I Trials of Chemoprevention Agents
Richard Chappell, University of Wisconsin, Madison, WI
Early Phase Trials Bridging the Gap between Prevention and Treatment
J. Jack Lee, UT M. D. Anderson Cancer Center, Houston, TX
Lessons Learned from Large Cancer Prevention Trials
Chairperson: Leslie G. Ford, National Cancer Institute, Bethesda, MD
Overview
Leslie G. Ford
BCPT and STAR: Lessons Learned in Breast Cancer Prevention
D. Lawrence Wickerham, University of Pittsburgh, Pittsburgh, PA
Issues in Designing Colorectal Adenoma Prevention Trials
Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA
Cancer Prevention Trials: Assume Nothing, Expect Everything
Phyllis J. Goodman, Fred Hutchinson Cancer Research Center, Seattle, WA
New Chemopreventive Concepts and Agents
Co-Chairpersons: Reuben Lotan, UT M. D. Anderson Cancer Center, Houston, TX, and Lee W. Wattenberg, University of Minnesota, Minneapolis, MN
An Interlocker Concept of Carcinogenesis
Lee W. Wattenberg
GPCR5A Knockout Mouse: A New Model for Lung Carcinogenesis
Reuben Lotan
Inhibition of Pulmonary Carcinogenesis in Mouse Models of Lung Cancer by Antitumor B
Ming You, Washington University, Saint Louis, MO
Antiangiogenic and Immune Modulating Effects of 3,3'-diindolylmethane
Leonard F. Bjeldanes, University of California, Berkeley, CA
PROFESSIONAL ADVANCEMENT SESSION FOR YOUNG INVESTIGATORS
12:15 p.m. to 2:00 p.m.
Chairperson: Waun Ki Hong, MD, Head, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX
PANEL PRESENTATION
12:15 p.m. to 1:15 p.m.
Panelists:
- Judy Garber, MD, MPH, Associate Professor of Medicine, Dana-Farber Cancer Institute, Boston, MA
- Ernest T. Hawk, MD, MPH, Director, Office of Centers, Training and Resources, National Cancer Institute, Bethesda, MD
- Howard K. Koh, MD, MPH, FACP, Harvey V. Fineberg Professor of the Practice of Public Health, Associate Dean for Public Health Practice, and Director of the Division of Public Health Practice, Harvard School of Public Health, Boston, MA
- Margaret R. Spitz, MD, Professor and Chair, Department of Epidemiology, UT M. D. Anderson Cancer Center, Houston, TX
ROUNDTABLE DISCUSSIONS
1:15 p.m. to 2:00 p.m.
Discussion leaders to be announced
EDUCATIONAL SESSIONS
2:00 p.m. to 3:30 p.m.
Intraepithelial Neoplasia: A Plan to Move Forward
Chairperson: Gary J. Kelloff, National Cancer Institute, Rockville, MD
Overview
Gary J. Kelloff
DNA Microarray Analysis in Breast Cancer Chemoprevention
Melissa A. Troester, University of Massachusetts, Amherst, MA
in vivo Peptide Mediated Confocal Microendoscopy of Colonic Dysplasia
Thomas Wang, Stanford University, Stanford, CA
Progress in Lung Cancer Chemoprevention
Stephen Lam, British Columbia Cancer Research Agency, Vancouver, BC, Canada
“Omics” Technologies: Overcoming Challenges to Implementation
Co-Chairpersons: Graham A. Colditz, Harvard Medical School, Boston, MA, and Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX
Overview
Graham A. Colditz
Integrative Epidemiology
Gordon B. Mills
Improving the Reliability and Efficiency of Proteomics and Genomics Research About Diagnosis and Prognosis
David F. Ransohoff, University of North Carolina, Chapel Hill, NC
Validation of the 21 Gene Oncotype DX Breast Cancer Assay: Clinical Trial Cohorts and Population-Based Studies
Steven Shak, Genomic Health, Redwood City, CA
Tobacco Carcinogenesis: Biomarkers, Susceptibility, and Mechanisms
Chairperson: Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, NY
Tobacco Carcinogen Biomarkers
Stephen S. Hecht, University of Minnesota Cancer Center, Minneapolis, MN
Genetic Susceptibility to Tobacco Carcinogenesis: An Integrative Epidemiologic Approach
Margaret R. Spitz, UT M. D. Anderson Cancer Center, Houston, TX
Tobacco Smoke, Cell Signaling, and Biomarker Development
Andrew J. Dannenberg
Discussion
OPENING KEYNOTE SESSION
4:00 p.m. to 6:45 p.m.
Welcome and Remarks
4:00 p.m. to 4:15 p.m.
Margaret Foti, CEO, American Association for Cancer Research and Scott M. Lippman, Program Committee Chairperson
Distinguished Lecture on Targets for Cancer Prevention
4:15 p.m. to 5:15 p.m.
Can the Switch to the Angiogenic Phenotype be Prevented?
Judah Folkman, Harvard Medical School, Boston, MA
Keynote Address
5:15 p.m. to 6:15 p.m.
Future Worldwide Health Effects of Current Smoking Patterns: The Hazards of Smoking and the Benefits of Stopping
Sir Richard Peto, University of Oxford, Oxford, England
Cancer Control Strategies Worldwide
6:15 p.m. to 6:45 p.m.
Prabhat Jha, University of Toronto, Toronto, ON, Canada
OPENING RECEPTION
7:00 p.m. to 9:00 p.m.